AbbVie Synthetic Arm

AbbVie: Synthetic Control Arm: The End of Placebos?

No one who signs up for a clinical trial wants to be placed in the placebo group. Placebos are like our savings accounts, our daily workout, why we wash dishes: the end result justifies the means. That doesn’t mean we have to love the process. In fact, the fear of being placed in a placebo group is why some people avoid clinical trials all together.To really know if a drug is working, researchers have to study groups of similar people, where the only difference is the drug being tested. That way, any differences in outcome can be clearly attributed to the experimental treatment. This is achieved through randomization – randomly assigning clinical trial participants to groups that receive the treatment, or groups that don’t, also known as receiving a “placebo.” “The purpose of clinical research is to provide clear answers to patients, physicians and regulators alike,” says Erik Pulkstenis, Ph.D., vice president of data and statistical sciences, AbbVie. “Historically that’s been done using randomized placebo-controlled studies because of the comfort they provide with respect to interpretability.”

But what if, in some situations, we could substitute a traditional placebo group with a “synthetic control arm” that includes pre-existing data?

What is a Synthetic Control Arm?

The question at the heart of most clinical trials relates to determining the treatment effect for one agent versus a placebo control. In the case of synthetic control arms, placebo arms are modeled using information that has previously been collected, instead of patients receiving a placebo. This data comes from sources including historical control data, real world data, or the generation of a companion data set from other sources to serve as a comparator.

There are already situations where the placebo can be avoided altogether. In oncology, for example, approvals are sometimes based on single-arm trials, where everyone receives the experimental therapy.

“When we’re looking at tumors, the response rate for untreated patients is known to be essentially zero, reflecting that tumors do not shrink on their own. As a result, if all patients in a trial are given a treatment, tumor reduction of sufficient magnitude and duration is believed to indicate treatment effect and can support approval,” Pulkstenis explains. “In this case the ‘control’ group is based on what we know historically about the course of untreated disease and the lack of placebo effect in this setting.”

Parachutes: We Know They Work

Could this new system make the need for control arms redundant? The short answer, says Pulkstenis, is unfortunately no.

“Randomization is very powerful and stands as an almost sacred principle when it comes to clinical trials,” Pulkstenis said. “It serves as the foundation for all analysis that is performed, and the resulting conclusions from the study. Conclusions are only valid in the presence of truly similar groups, so leaving the safety of randomization is not something to be taken lightly.”

To illustrate the inherent risks of synthetic controls, say you are researching whether parachutes improve outcomes for people who jump out of planes. You know, based on past data, that the survival for people without parachutes in planes of a certain height is zero. If five people with parachutes jump out of a plane and all survive, it’s a clear sign that parachutes vastly increase someone’s chances of survival.

In this parachute example, the synthetic control is all the historical data we have on those unlucky people who didn’t use a parachute. But here’s the critical part – people in the control group have to be very similar to those in the new study for the results to be accurate. If, in your group with parachutes, people jumped at 10,000 feet and in the historical control group, people jumped when the plane was stationary on the runway, it would be a non-valid synthetic arm.

However, there are limited situations where the benefits of a synthetic arm might outweigh the risks: if a disease is rare, and traditional trial methods may be prohibitive; areas where control group performance is well characterized historically, and results are generally consistent from trial to trial; or cases where there are clean objective endpoints that are easy to measure.

The Role of Machine Learning and Artificial Intelligence

Machine learning helps researchers access huge amounts of multi-dimensional data that had once been too big and complex to use effectively. Could machine learning be used to generate a suitable control group?

“I hesitate to say there is anything machine learning cannot do because it has proven itself to continually surprise us and it is feasible that machine learning could draw a suitable control group from large, well-characterized sources of data,” Pulkstenis says. “However, it can’t help with unmeasured or unknown data, which quite often can drive important differences in a population. This would be like teaching machine learning to play a game but not telling it all the rules.”

The concept of synthetic control arms is gaining traction in the pharmaceutical research community; even the FDA is interested in the possibilities it presents.

“Five years ago, there wasn’t much talk of technologies like synthetic controls or telemedicine or wearable sensors to collect data and today, at least at AbbVie, a digital component is considered for every clinical trial we put together,” says Rob Scott, M.D., chief medical officer and vice president of AbbVie’s Development team. “There is no doubt these technologies will redefine how trials are run by including better data that is more relevant to patients and researchers.”

AbbVie currently is running two trials designed in close partnership with regulators that include components of synthetic control. Using advanced analysis methods to characterize existing data, researchers have cut control groups in half, supplemented by information already learned about control performance. The new Development Design Center is also exploring the enrollment of matching virtual control subjects through access to real world contemporary data.

Like so many other innovations, synthetic control arms aren’t about completely replacing established ways of doing things, but about making them better. After all, dishwashers came along to more efficiently clean dishes, but we still sometimes get down and dirty with the dish soap. Checkbooks can be balanced via mobile apps, but there are times when a pen and paper get the job done.

“Synthetic control arms aren’t the solution to all of the challenges facing randomized trials, nor do they realize the full promise of real-world evidence in drug development,” Pulkstenis says. “But in certain situations, they might be a better option.”

Latest News

HIV, AIDS, Misconception

Fact Check: Misconceptions About HIV/AIDS

Similar to the coronavirus and the ongoing COVID-19 pandemic throughout 2020, many of the misconceptions and stigma surrounding HIV and AIDS have been fueled by fear. Although information surrounding the disease is more accessible now that we’re months into the pandemic, many people still misunderstand the condition, the treatment options,…

President-elect Joe Biden with senior adviser Symone Sanders

Biden and Harris Announce All-Female White House Communications Team; After 9 Long Months, COVID-19 Hits New Peak; and More

Biden and Harris announce entirely female-led White House communications team. President-elect Joe Biden’s transition to the White House continues at a brisk pace. On Monday, Nov. 30th, Biden and Vice President-elect Kamala Harris received their first daily Presidential intelligence briefings. A day earlier, CBS News has reported that the pair…

Cigna

Veterans Recovery Resources of Mobile Receives $100,000 Cigna Foundation Grant to Provide Mental Health Services to Area Veterans

Originally published on Cigna.com For the second year in a row, the Cigna Foundation will provide a $100,000 grant to Veterans Recovery Resources, a community-based, non-profit organization that offers professional clinical care and peer-based wellness programs to military service members, veterans, families, caregivers and survivors in southwest Alabama and surrounding areas. Building on the…

aging and infected human cells

Racism Can Trigger Premature Aging; Trump Administration Loses Battle With Women Detained for Speaking Spanish; and More

Two new studies highlight damaging impact of racism on cells and the body Racism not only increases stress levels in the body, but also causes the body to age faster according to the results of two alarming new studies. In the first, conducted at the University of Nebraska-Lincoln and the…

thanksgiving, truth

The Truth You May Not Know About Thanksgiving

On Thursday, Nov. 26, many Native Americans and their allies across the country will observe the 51st National Day of Mourning. While most Americans will sit down to Thanksgiving dinners — albeit (hopefully) smaller ones than in years past due to COVID-19 — this counter-observance is designed as an ongoing…

President-elect Joe Biden

President-Elect Joe Biden’s Potential New Cabinet Filled With Historic Firsts; New Report Details the Top 10 Careers Most Impacted by COVID-19; and More

President-elect Biden continues his push for an administration that “looks like America.” With more than a month to go until he is even sworn in as the 46th president of the United States and his transition to the office finally underway after weeks of delay, President-elect Joe Biden is already…